Humacyte, Inc. (HUMA)
After hours:
| Previous Close | 9.10 |
| Open | 9.97 |
| Bid | 7.45 x 400 |
| Ask | 7.48 x 200 |
| Day's Range | 7.17 - 9.97 |
| 52 Week Range | 1.96 - 9.97 |
| Volume | |
| Avg. Volume | 1,921,423 |
| Market Cap | 890.748M |
| Beta (5Y Monthly) | 1.27 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.00 |
| Earnings Date | Aug 12, 2024 - Aug 16, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 8.00 |
GlobeNewswireHumacyte to Present at the Jefferies Global Healthcare Conference
DURHAM, N.C., May 30, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced that Laura Niklason, M.D., Ph.D., Founder, President, and Chief Executive Officer, will present at the Jefferies Global Healthcare Conference, in New York, NY on Thursday, June 6, 2024. Management will also be available for one-on-one meetings. Event: Jefferies Global Healt
Simply Wall St.This Humacyte Insider Increased Their Holding By 91% Last Year
From what we can see, insiders were net buyers in Humacyte, Inc.'s ( NASDAQ:HUMA ) during the past 12 months. That is...
- GlobeNewswire
Humacyte to Participate at Upcoming Investor Conferences in May
DURHAM, N.C., May 13, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced that Laura Niklason, M.D., Ph.D., Founder, President, and Chief Executive Officer, Dale Sander, Chief Financial Officer, and B.J. Scheessele, Chief Commercial Officer, will represent Humacyte at the following conferences in May. H.C. Wainwright BioConnect Investor Conferenc
